Drug Trial Radar · NCT04896255
Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B
Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
33,000
Planned (sponsor's estimate)
Start
Sep 9, 2020
Primary completion
Nov 1, 2026
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Huashan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chinese Foundation for Hepatitis Prevention and Control; The Third People's Hospital of Taiyuan; First Affiliated Hospital of Chongqing Medical University; Beijing YouAn Hospital; Henan Provincial People's Hospital; Yunnan Provincial No.1 Hospital; Third Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Xiamen University; Beijing Ditan Hospital; Tianjing No.2 People's Hospital; Qingdao No.6 People's Hospital; The Fourth Affiliated Hospital of Zhejiang University School of Medicine; Ningbo Beilun District Traditional Chinese Medicine Hospital; Wuxi No.5 People's Hospital; Taicang No.1 People's hospital; First Affiliated Hospital Xi'an Jiaotong University
- First posted
- May 21, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational, multicenter , real-world study is to evaluate the long-term outcomes of different antiviral therapies in adults with chronic hepatitis B (CHB). The main questions it aims to answer are: What is the 5-year incidence of hepatocellular carcinoma (HCC) under various treatment regimens? How do rates of HBsAg seroclearance, decompensated cirrhosis, liver fibrosis progression, and other virological and clinical outcomes compare across regimens? Researchers will compare real-world treatment arms-including nucleos(t)ide analogue (NA) monotherapy (e.g., entecavir, tenofovir), PegIFN based regimen (e.g., PegIFN monotherapy, PegIFN plus NA combinations)-to identify optimal strategies for reducing HCC risk and improving functional cure rates. Participants will undergo routine clinical care with no study-imposed interventions; data on demographics, medical history, symptoms, laboratory tests (e.g., HBsAg, HBV DNA, liver function), imaging (e.g., ultrasound, elastography), and clinical events will be collected prospectively (for up to 5 years in some cohorts) or retrospectively from medical records at baseline and scheduled follow-up visits (e.g., every 3-12 months initially, then annually).
Conditions
- Chronic Hepatitis b
Interventions
peginterferon alpha based regimenDrug
peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
nucleos(t)ideDrug
peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- rate of hepatocellular carcinoma at 5 year from baselineTime frame: 5 year from baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.